Author: claimsbot

What is claimed is:

1. A method for inhibiting body odors in a subject comprising administering to said subject cosmeticspersonal care products into which are incorporated a complexing agent having the formula
213
wherein,
p and q are independently integers of from 2 to 3;
r is an integer of from 1 to 4;
R2, R3, and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R1 is a member selected from the group consisting of R2, R3, R4, and radicals of the formula:
214
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
215
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R1, R2, R3 and R4 are combined to form a ring structure;
and dimers of Formula I, said dimers being formed by the covalent attachment of two complexing agents of Formula I through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
2. A method of inhibiting tooth decay, gum disease and periodontal disease in a subject, comprising administering to said subject an oral care product incorporating a complexing agent having the formula:
216
wherein,
p and q are independently either 2 or 3;
r is an integer of from 1 to 4;
R2, R3, and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R1 is a member selected from the group consisting of R2, R3, R4, and radicals of the formula:
217
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
218
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, alkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R1, R2, R3 and R4 are combined to form a ring structure;
and dimers of Formula I, said dimers being formed by the covalent attachment of two complexing agents of Formula I through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
3. A method of inhibiting oxidative damage to skin and skin appendages in a subject, comprising administering to said subject a skin and skin appendage care product incorporating a complexing agent having the formula:
219
wherein,
p and q are independently either 2 or 3;
r is an integer of from 1 to 4;
R2, R3, and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R1 is a member selected from the group consisting of R2, R3, R4, and radicals of the formula:
220
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
221
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R1, R2, R3 and R4 are combined to form a ring structure;
and dimers of Formula I, said dimers being formed by the covalent attachment of two complexing agents of Formula I through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
4. A method of inhibiting metalloenzymes containing first transition series metal cations in a subject, comprising administering or applying to said subject a complexing agent having the formula:
222
wherein,
p and q are independently either 2 or 3;
r is an integer of from 1 to 4;
R2, R3, and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R1 is a member selected from the group consisting of R2, R3, R4, and radicals of the formula:
223
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
224
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R1, R2, R3 and R4 are combined to form a ring structure;
and dimers of Formula I, said dimers being formed by the covalent attachment of two complexing agents of Formula I through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
5. A method of inhibiting reperfusion injury in a subject, comprising administering to said subject a complexing agent having the formula:
225
wherein,
p and q are independently integers of from 2 to 3;
r is an integer of from 1 to 4;
R2, R3, and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R1 is a member selected from the group consisting of R2, R3, R4, and radicals of the formula:
226
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
227
wherein,
R41, R42, and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R1, R2, R3 and R4 are combined to form a ring structure;
and dimers of Formula I, said dimers being formed by the covalent attachment of two complexing agents of Formula I through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
6. A method for inhibiting body odors in a subject comprising administering to said subject a cosmeticpersonal care product into which is incorporated a complexing agent having the formula
228
wherein,
t, u and v are each independently 2 or 3;
w is an integer of from 1 to 4;
R11 and R13 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R11 is a member selected from the group consisting of R11, R12 and radicals of the formula:
229
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
230
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R11, R12 and R13 are combined to form a ring structure;
and dimers of Formula II, said dimers being formed by the covalent attachment of two complexing agents of Formula II through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
7. A method for inhibiting tooth decay, gum disease and periodontal disease in a subject comprising administering to said subject an oral care product into which is incorporated a complexing agent having the formula
231
wherein,
t, u and v are each independently 2 or 3;
w is an integer of from 1 to 4;
R11 and R13 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R11 is a member selected from the group consisting of R11, R12 and radicals of the formula:
232
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
233
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, alkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R11, R12, and R13 are combined to form a ring structure;
and dimers of Formula II, said dimers being formed by the covalent attachment of two complexing agents of Formula II through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
8. A method for inhibiting oxidative damage to skin and skin appendages in a subject comprising administering to said subject a skin and skin appendage product into which is incorporated a complexing agent having the formula
234
wherein,
t, u and v are each independently 2 or 3;
w is an integer of from 1 to 4;
R11 and R13 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R11 is a member selected from the group consisting of R11, R12 and radicals of the formula:
235
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
236
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R11, R12, and R13 are combined to form a ring structure;
and dimers of Formula II, said dimers being formed by the covalent attachment of two complexing agents of Formula II through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
9. A method for inhibiting metalloenzymes containing first transition series elements in a subject comprising administering to said subject a complexing agent having the formula
237
wherein,
t, u and v are each independently 2 or 3;
w is an integer of from 1 to 4;
R11 and R13 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R11 is a member selected from the group consisting of R11, R12 and radicals of the formula:
238
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
239
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R11, R12, and R13 are combined to form a ring structure;
and dimers of Formula II, said dimers being formed by the covalent attachment of two complexing agents of Formula II through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
10. A method for inhibiting reperfusion injury in a subject comprising administering to said subject a complexing agent having the formula
240
wherein
t, u and v are each independently 2 or 3;
w is an integer of from 1 to 4;
R11 and R13 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R11 is a member selected from the group consisting of R11, R12 and radicals of the formula:
241
wherein,
R41, R42, and R43 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, and halogen-substituted versions thereof;
R44 is a member selected from the group consisting of H, hydroxy, amino, alkyl interrupted by oxa, alkoxy, aryl, aryloxyalkyl, alkoxyaryl, alkoxyaryl, and halogen-substituted versions thereof;
n is zero or 1; and
X is a member selected from the group consisting of alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenoxy, alkenylthio, aryloxy, arylthio, alkyl interrupted by oxa, alkenyl interrupted by oxa, alkyl interrupted by thia, alkenyl interrupted by thia, aryloxyalkyl, alkoxyaryl, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylalkyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, hydroxyarylalkyl, halogen-substituted versions thereof, and radicals selected form the group consisting of:
242
wherein,
R41, R42, R43 and R44 are each independently as defined above;
R46 and R47 are each independently selected from the group consisting of H, alkyl and aryl, or taken together form a ring structure;
R48 and R49 are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkyl interrupted by oxa, aryloxyalkyl, alkoxyaryl, and halogen-substituted versions thereof;
R50, R51 and R52 are each independently selected from the group consisting of H, alkyl, alkenyl, aryl, arylalkyl, alkoxy, alkylthio, alkenyloxy, allkenylthio, aryloxy, aminoalkyl, aminoalkenyl, aminoaryl, aminoarylakyl, hydroxyalkyl, hydroxyalkenyl, hydroxyaryl, and hydroxyarylalkyl; and
m is an integer of from 1 to 3
and wherein, optionally, any two of R11, R12, and R13 are combined to form a ring structure;
and dimers of formula II, said dimers being formed by the covalent attachment of two complexing agents of Formula II through a linking group having from 1 to 6 carbon atoms; and physiological salts thereof;
with the proviso that the molecular weight of said complexing agent does not exceed 2000.
11. A method in accordance with claim 6 in which said complexing agent is N,N,N-tri(dihydroxyphosphoryl methyl)-1,4,7-triazacyclononane.
12. A method in accordance with claim 7 in which said complexing agent is N,N,N-tri(dihydroxyphosphoryl methyl)-1,4,7-triazacyclononane.
13. A method in accordance with claim 8 in which said complexing agent is N,N,N-tri(dihydroxyphosphoryl methyl)-1,4,7-triazacyclononane.
14. A method in accordance with claim 9 in which said complexing agent is N,N,N-tri(dihydroxyphosphoryl methyl)-1,4,7-triazacyclononane.
15. A method in accordance with claim 10 in which said complexing agent is N,N,N-tri(dihydroxyphosphoryl methyl)-1,4,7-triazacyclononane.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A system for managing care of a person receiving emergency cardiac assistance, the system comprising:
one or more capacitors for delivering a defibrillating shock to a patient;
one or more electronic ports for receiving signals from sensors for obtaining indications of an electrocardiogram (ECG) for the patient; and
a patient treatment module executable on one or more computer processors to provide a determination of a likelihood of success from delivering a future defibrillating shock to the person with the one or more capacitors, using (a) information about a prior defibrillating shock, and (b) a value that is a function of current ECG signals from the patient.
2. The system of claim 1, further comprising an output mechanism arranged to indicate, to a user of the system, an indication regarding the likelihood of success form delivering a defibrillating shock to the person with the one or more capacitors.
3. The system of claim 2, wherein the output mechanism comprises a visual display, and the system is programmed to display to the user one of multiple possible indications that each indicate a degree of likelihood of success.
4. The system of claim 1, wherein the output mechanism comprises an interlock that prevents a user from delivering a shock unless the determined likelihood of success exceeds a determined value.
5. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an amplitude spectrum area (AMSA) value, and wherein the patient treatment module uses the information about the level of success from the prior defibrillating shock to adjust the AMSA value.
6. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an indication of heart rate for the patent.
7. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an indication heart rate variability for the patent.
8. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an indication of ECG amplitude for the patent.
9. The system of claim 8, wherein the indication of ECG amplitude comprises an RMS measurement, measured peak-to-peak, peak-to-trough, or an average of peak-to-peak or peak-to-trough over a specified interval
10. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an indication of a first derivative of ECG amplitude for the patent.
11. The system of claim 1, wherein the patient treatment module comprises an ECG analyzer for generating an indication of a second derivative of ECG amplitude for the patent.
12. The system of claim 1, where the patient treatment module is programmed to determine whether a prior defibrillation shock was at least partially successful, and based at least in part on the determination of whether the prior defibrillation was at least partially successful, modifying a calculation of the likelihood of success from delivering the future defibrillating shock.
13. The system of claim 1, wherein determining a likelihood of success from delivering a future defibrillating shock to the person depends on a determination of whether one or more prior shocks delivered to the person were successful in defibrillating the person.
14. The system of claim 1, wherein determining a likelihood of success from delivering a future defibrillating shock comprises performing a mathematical transform on the ECG data.
15. The system of claim 14, wherein the mathematical transform is selected form a group consisting of Fourier, discrete Fourier, Hilbert, discrete Hilbert, wavelet, and discrete wavelet methods.
16. The system of claim 1, wherein determining a likelihood of success from delivering a future defibrillating shock comprises performing a calculation by an operation selected form a group consisting of logistic regression, table look-up, neural network, and fuzzy logic.
17. The system of claim 1, wherein the patient treatment module is programmed to determine the likelihood of success from delivering a future defibrillating shock using at least one patient-dependent physical parameter separate from a patient ECG reading.
18. The system of claim 1, wherein the patient treatment module is programmed to determine the likelihood of success from delivering a future defibrillating shock using at a measure of trans-thoracic impedance of the person.
19. A method for managing care of a person receiving emergency cardiac assistance, the method comprising:
monitoring, with an external defibrillator, electrocardiogram (ECG) data from a person receiving emergency cardiac assistance;
determining whether a prior defibrillation shock occurred;
determining a likelihood of future defibrillation shock success using at least the ECG data;
based at least in part on the determination of whether the prior defibrillation occurred, modifying the calculation of the chance of defibrillation shock success; and
affecting control of the external defibrillator based on the identification of whether a present defibrillation shock will likely be effective.
20. The method of claim 19, wherein determining a likelihood of future defibrillation shock success comprises determining a value that is a function of electrocardiogram amplitude at particular different frequencies or frequency ranges.
21. The method of claim 20, wherein determining a likelihood of future defibrillation shock success comprises determining an amplitude spectrum area (AMSA) value for the ECG data.
22. The method of claim 21, wherein determining a likelihood of future defibrillation shock success further comprises adjusting the determined AMSA value using information about the prior defibrillation shock.
23. The method of claim 22, further comprising determining whether the adjusted AMSA value exceeds a predetermined threshold value.
24. The method of claim 23, further comprising providing to the rescuer a visual, audible, or tactile alert that a shockable situation exists for the person, if the adjusted AMSA value is determined to exceed the predetermined threshold value.
25. The method of claim 19, further comprising determining whether a prior defibrillation shock was at least partially successful, and based at least in part on the determination of whether the prior defibrillation was at least partially successful, modifying a calculation of the likelihood of success from delivering the future defibrillating shock.
26. The method of claim 19, wherein determining a likelihood of success from delivering a future defibrillating shock comprises performing a mathematical transform on the ECG data.
27. The method of claim 26, wherein the mathematical transform is selected form a group consisting of Fourier, discrete Fourier, Hilbert, wavelet, and discrete wavelet methods.
28. The method of claim 27, wherein determining a likelihood of success from delivering a future defibrillating shock comprises performing a calculation by an operation selected form a group consisting of logistic regression, table look-up, neural network, and fuzzy logic.
29. The method of claim 19, where the likelihood of success from delivering a future defibrillating shock is determined using at least one patient-dependent physical parameter separate from a patient ECG reading.
30. The method of claim 19, wherein the additional physiologic parameter is trans-thoracic impedance of the person receiving emergency cardiac care.
31. The method of claim 19, wherein the indication of trans-thoracic impedance is determined from signals sensed by a plurality of electrocardiogram leads that also provide the EGO data.
32. The method of claim 19, further comprising cyclically repeating the actions of monitoring, determining, identifying and providing the indication.
33. The method of claim 19, further comprising identifying compression depth of chest compressions performed on the person, using a device on the person’s sternum and in communication with the external defibrillator, and providing feedback to a rescuer performing the chest compressions regarding rate of compression, depth of compression, or both.
34. The method of claim 19, wherein affecting control of the defibrillator comprises preventing a user from delivering a shock unless the determination of whether a shock will be effective exceeds a determined likelihood level.
35. The method of claim 19, wherein affecting control of the defibrillator comprises electronically displaying, to a user, an indicator of the determined indication of whether a shock will be effective.
36. The method of claim 19, wherein displaying an indicator comprises displaying a value, of multiple possible values in a range, that indicates a likelihood of success.
37. The method of claim 19, wherein the calculation of the likelihood of current shock success is determined or modified using a determination of a value of trans-thoracic impedance of the person.

1. A wrench for a valve having a bonnet, the bonnet having a body with an outer surface and a rib attached to and extending from the outer surface, the rib having a side surface, the wrench comprising:
an elongated member having:

a first end portion and an opposing second end portion;
a t-shaped handle attached to the first end portion;
a first leg attached to the second end portion, the first leg having:

a rigid rectangular shape and a front surface and an inner surface;
a second leg having a rigid rectangular shape;
the second leg attached to the second end portion, the first leg and the second leg extend away from the second end at a non-zero angle with respect to each other, thereby forming a gap, the gap being unobstructed between the first leg and the second leg, so as to permit the bonnet to engage the first leg along the inner surface from the second end to an end portion of the first leg; and
a fastener which has a detachable end and a tapered plate attached to a second end opening of the first leg;
wherein the inner surface of the first leg engages the outer surface of the bonnet and the front surface of the first leg engages the side surface of the rib during removal of the bonnet from the valve.
2. The wrench according to claim 1, wherein the fastener is a screw driver bit.
3. The wrench according to claim 2, further comprising:
an extension member coupled to the first leg.
4. The wrench according to claim 1, further comprising:
a socket adapter attached to the handle.
5. The wrench according to claim 4, further comprising:
a cup housing coupled to the socket adapter.
6. The wrench according to claim 1, further comprising:
a first post attached to a first end of the handle extending in a direction relatively orthogonal to the length of the handle; and

a second post attached to a second end of the handle extending in a direction relatively orthogonal to the length of the handle.
7. The wrench according to claim 1, further comprising:
a quick-release device coupled to the first leg to allow for selective interchangeability of the fastener.
8. A method for disengaging a bonnet threadedly attached to a valve positioned in an underground housing, the bonnet having a body with an outer surface and a rib attached to and extending from the outer surface, the rib having a side surface, the method comprising:
providing a wrench having an elongated member including a t-shape handle being attached to a first leg and attached to a second leg, the first leg and the second leg extend away from the second end at a non-zero angle with respect to each other, thereby forming a gap, the first leg and the second leg being non-parallel from the second end to an end portion of the first leg wherein a fastener has a detachable end and a tapered plate attached, the gap being unobstructed between the first leg and the second leg, so as to permit the bonnet to engage the first leg along the inner surface from the second end to an end portion of the first leg;
locating the wrench over the bonnet until the bonnet engages the inner surface, thereby creating a tight fit there between;
rotating the wrench, such that a front surface of the first leg contacts the side surface of the rib, thereby disengaging the bonnet from the valve.
9. The method according to claim 8, further comprising:
providing a handle attached to the elongated member, the handle having a first post coupled to a first end of the handle;
engaging the first post with a lid in communication with the housing, the lid being releasably coupled the housing;
applying a turning force to the elongated member, thereby disengaging the lid from the housing; and

removing the lid from the housing.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A method for routing analog Caller ID signals comprises:
receiving an incoming telephone call for a first telephone extension, the incoming telephone call associated with a first set of analog Caller ID signals;
asserting a ringing signal to the first telephone extension, the ringing signal including the first set of analog Caller ID signals;
coupling the incoming call to the first telephone extension;
receiving a request to couple the incoming call from the first telephone extension to a second telephone extension;
receiving a request to send the first set of analog Caller ID signals to the second telephone extension; and
asserting a ringing signal to the second telephone extension, the ringing signal including the first set of analog Caller ID signals.
2. The method of claim 1 wherein the first set of analog Caller ID signals comprises numbers.
3. The method of claim 2 wherein the numbers are encoded with a frequency key shift.
4. The method of claim 1,
wherein the first set of analog Caller ID signals is also associated with caller data; and
wherein the method also includes outputting the caller data.
5. The method of claim 4 further comprising:
encoding the caller data into a second set of analog Caller ID signals;
wherein the ringing signal also includes the second set of analog Caller ID signals.
6. The method of claim 1 wherein the ringing signal for the second telephone extension also includes a second set of analog Caller ID signals, the second set of analog Caller ID signals associated with the first telephone extension.
7. The method of claim 1 further comprising:
after receiving the incoming telephone call for the first telephone extension, decoding the first set of analog Caller ID signals for caller data; and
before asserting the ringing signal to the second telephone extension, encoding the caller data to regenerate the first set of analog Caller ID signals.
8. A computer program product for routing analog identification data in a telecommunication server including a processor comprises:
code that directs the processor to detect an incoming telephone call for a first telephone extension, the incoming telephone call associated with a first set of analog identification data;
code that directs the processor to assert a ringing signal to the first telephone extension, the ringing signal including the first set of analog identification data;
code that directs the processor to couple the incoming call to the first telephone extension;
code that directs the processor to detect a request to couple the incoming call from the first telephone extension to a second telephone extension;
code that directs the processor to detect a request to transfer the first set of analog information data to the second telephone extension; and
code that directs the processor to assert a ringing signal to the second telephone extension, the ringing signal including the first set of analog information data,
wherein the codes are stored in a tangible media.
9. The computer program product of claim 8 further comprising code that directs the processor to output caller data;
wherein the first set of analog identification data is also associated with the caller data.
10. The computer program product of claim 9 further comprising:
code that directs the processor to encode the caller data into a second set of analog identification data;
wherein the ringing signal also includes the second set of analog identification data.
11. The computer program product of claim 8 wherein the ringing signal for the second telephone extension also includes a second set of analog identification data, the second set of analog identification data associated with the first telephone extension.
12. The computer program product of claim 11 wherein the second set of analog identification data comprises alphanumeric characters.
13. The computer program product of claim 8 further comprising:
code that directs the processor to decode the first set of analog identification data for caller data;
code that directs the processor to store the caller data; and
code that directs the processor to re-encodes the caller data to regenerate the first set of analog identification data.
14. A telecommunication server including a processor for routing an analog information signal comprises:
a computer readable memory including:
code that directs the processor to detect a telephone call from an external telephone for a first internal telephone, the telephone call associated with an analog information signal;
code that directs the processor to decode the analog information signal for caller data;
code that directs the processor to store the caller data;
code that directs the processor to form a re-generated analog information signal in response to the caller data;
code that directs the processor to provide a ringer signal to the first internal telephone, the ringer signal including the re-generated analog information signal;
code that directs the processor to couple the telephone call to the first internal telephone;
code that directs the processor to detect a request to forward the telephone call from the first internal telephone to a second internal telephone;
code that directs the processor to detect a request to forward the caller data to the second internal telephone; and
code that directs the processor to assert a ringer signal to the second internal telephone, the ringer signal including the re-generated analog information signal.
15. A telecommunication server of claim 14,
wherein the caller data is also associated with other caller data in the computer readable memory; and
wherein the computer readable memory also includes code that directs the processor to output the other caller data.
16. The telecommunication server of claim 15
wherein the code that directs the processor to output the other caller data comprises code that directs the processor to form an additional analog information signal in response to the other caller data; and
wherein the ringing signal also includes the additional analog information signal.
17. The telecommunication server of claim 14 wherein the first internal telephone has associated telephone data; and
the computer readable memory also includes code that directs the processor to form an additional analog information signal in response to the associated telephone data;
wherein the ringer signal for the second internal telephone includes the additional analog Information signal.
18. The telecommunication server of claim 17 wherein the additional analog information signal comprises characters from the class of ASCII characters.
19. The telecommunication server of claim 14 wherein code that directs the processor to form the re-generated analog information signal is also in response to data associated with the caller data.
20. The telecommunication server of claim 14 wherein the computer readable memory also includes:
code that directs the processor to prompt a user of the first internal telephone whether the caller data should be forwarded to the second internal telephone.
21. The telecommunication server of claim 20 wherein the caller data comprises Caller ID data.